Patents Assigned to Duke University
  • Patent number: 11122997
    Abstract: Materials and methods for treating major depressive disorder by modulating the aryl hydrocarbon receptor system are provided herein.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: September 21, 2021
    Assignees: Mayo Foundation for Medical Education and Research, Ixcela Inc., Duke University
    Inventors: Balmiki Ray, Liewei Wang, Joanna Biernacka, Mark Frye, Richard M. Weinshilboum, Michiaki Kubo, Taisei Mushiroda, Wayne R. Matson, Rima Kaddurah-Daouk
  • Patent number: 11123333
    Abstract: The disclosure provides compounds that inhibit the invasion of host cells by intracellular parasites. These find use, for example, in treating and preventing periodontitis or a periodontitis-related condition or symptom.
    Type: Grant
    Filed: February 17, 2019
    Date of Patent: September 21, 2021
    Assignees: Meharry Medical College, Duke University
    Inventors: Hua Xie, Chin-Ho Chen
  • Publication number: 20210284980
    Abstract: Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research.
    Type: Application
    Filed: March 23, 2021
    Publication date: September 16, 2021
    Applicant: Duke University
    Inventors: James Jefferson Smith, Derek Jantz, Homme W. Hellinga
  • Patent number: 11117911
    Abstract: High-potential photo-oxidants are provided with a supermolecule structure at least including a conjugated macrocycle linked to a metal complex. The conjugated macrocycle is electron-accepting relative to hydrogen or bears electron withdrawing substituents such as fluoroalkyl, fluoroaryl, fluoro, halo, cyano, or nitro. The metal complex is also electron-accepting relative to hydrogen or bears electron withdrawing substituents such as fluoroalkyl, fluoroaryl, fluoro, halo, cyano, or nitro. The linker can be thynyl, vinyl, thiophenyl, diethynylaryl, divinylaryl, diethynyl(unsaturated heterocycloalkenyl), divinyl(unsaturated heterocycloalkenyl), diethynyl(unsaturated heterocycloalkynyl), or divynyl(unsaturated heterocycloalkynyl). A specific implementation is an ethyne-bridged eDef-Rutpy-(porphinato)Zn(II) (eDef-RuPZn) supermolecule.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: September 14, 2021
    Assignee: DUKE UNIVERSITY
    Inventors: Michael Therien, Ting Jiang, Nicholas Polizzi, Jeffrey Rawson
  • Publication number: 20210278419
    Abstract: This invention provides reagents, methods and biochemical markers for identifying and providing therapeutic intervention for individuals with metabolic dysfunction, or individuals at risk for metabolic dysfunction.
    Type: Application
    Filed: March 14, 2021
    Publication date: September 9, 2021
    Applicant: Duke University
    Inventors: John F. Rawls, James E.N. Minchin
  • Publication number: 20210275583
    Abstract: The present disclosure provides compositions and methods for treating demyelinating conditions. More particularly, the present disclosure relates to compositions comprising a DUOC-01 cell product; methods for preparing such compositions; and methods of using such compositions for treating demyelinating conditions.
    Type: Application
    Filed: May 24, 2021
    Publication date: September 9, 2021
    Applicant: Duke University
    Inventors: Joanne Kurtzberg, Anthony Fillano, Arjun Saha, Andrew E. Balber, Ana Valverde
  • Publication number: 20210268066
    Abstract: The present disclosure provides methods and kits for treating pain. More particularly, the present disclosure relates to methods of using PD-L1/PD-1-associated compounds to treat pain and/or bone destruction from bone cancer, and associated kits. The present disclosure also provides methods to assess the efficacy of compounds to suppress PD-1-associated nociceptive neuron activity.
    Type: Application
    Filed: May 11, 2021
    Publication date: September 2, 2021
    Applicant: Duke University
    Inventors: Ru-Rong Ji, Gang Chen, Zilong Wang, Changyu Jiang, Kaiyuan Wang
  • Patent number: 11103558
    Abstract: The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: August 31, 2021
    Assignee: Duke University
    Inventor: Ashutosh Chilkoti
  • Patent number: 11103708
    Abstract: Systems and methods for determining optimal temporal patterns of neural stimulation are disclosed. According to an aspect, a method includes selecting a temporal pattern for neural stimulation. The method also includes determining a mutation type for altering a pattern of pulses of the temporal pattern. The method also includes identifying a location within the pattern of pulses of the temporal pattern to alter based on the determined mutation type. The method further includes altering the pattern of pulses of the temporal pattern based on the identified location and mutation type for application of the altered temporal pattern to a subject.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: August 31, 2021
    Assignee: Duke University
    Inventors: Warren M. Grill, Isaac Cassar, Nathan Titus
  • Patent number: 11099176
    Abstract: The present subject matter provides lactate biosensors as well as compositions, devices, and methods comprising such biosensors.
    Type: Grant
    Filed: November 19, 2016
    Date of Patent: August 24, 2021
    Assignee: Duke University
    Inventors: Homme W. Hellinga, Malin J. Allert
  • Patent number: 11098307
    Abstract: This invention relates to metabolically engineered microorganisms, such as bacterial and or fungal strains, and bioprocesses utilizing such strains. These strains enable the dynamic control of metabolic pathways, which can be used to optimize production. Dynamic control over metabolism is accomplished via a combination of methodologies including but not limited to transcriptional silencing and controlled enzyme proteolysis. These microbial strains are utilized in a multi-stage bioprocess encompassing at least two stages, the first stage in which microorganisms are grown and metabolism can be optimized for microbial growth and at least one other stage in which growth can be slowed or stopped, and dynamic changes can be made to metabolism to improve the production of desired product, such as a chemical or fuel.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: August 24, 2021
    Assignee: DUKE UNIVERSITY
    Inventors: Michael David Lynch, Ashley Trahan, Daniel Rodriguez, Zhixia Ye, Charles Cooper, Ahmet Bozdag
  • Publication number: 20210251922
    Abstract: The present disclosure is directed to methods of treating a steatosis-associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage.
    Type: Application
    Filed: March 2, 2021
    Publication date: August 19, 2021
    Applicants: Duke University, National University of Singapore
    Inventors: Dwight D. Koeberl, Paul M. Yen, Benjamin L. Farah
  • Publication number: 20210244772
    Abstract: The present disclosure provides methods for the treatment of autism spectrum disorders. More particularly, the present disclosure relates to methods of using cord blood for the treatment of autism spectrum disorders.
    Type: Application
    Filed: February 8, 2021
    Publication date: August 12, 2021
    Applicant: DUKE UNIVERSITY
    Inventors: Joanne Kurtzberg, Geraldine Dawson, Jesse Troy, Jessica Sun
  • Publication number: 20210246194
    Abstract: The present invention is directed to optimized HIV-1 gp41-Binding Molecules having reduced immunogenicity. More specifically, the invention relates to optimized gp41-Binding Molecules that comprise a gp41-binding Variable Light Chain (VL) Domain and/or a gp41-binding Variable Heavy Chain (VH) Domain that has/have been optimized to reduce the immunogenicity of such Domain(s) upon administration to a recipient subject. The invention particularly pertains to gp41-Binding Molecules that are multispecific gp41-Binding Molecules (including bispecific diabodies (including DART® diabodies), BiTE®s, bispecific antibodies, trivalent binding molecules (including TRIDENT™ molecules), etc.) that comprise: (i) such optimized gp41-binding Variable Domain(s) and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell.
    Type: Application
    Filed: May 13, 2019
    Publication date: August 12, 2021
    Applicants: MacroGenics, Inc., Duke University
    Inventors: Chia-Ying Kao Lam, Gundo Diedrich, Jeffrey Lee Nordstrom, Liqin Liu, Leslie S. Johnson, Scott Koenig, Barton F. Haynes, Guido Ferrari
  • Patent number: 11083803
    Abstract: A sterile aqueous composition suitable for use as an MRI contrast agent includes 100 to 600 mM ascorbate; and 100-600 mM sodium, meglumine, or a combination thereof. The composition preferably has an osmolarity of 200 to 1400 mOsm/L.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: August 10, 2021
    Assignee: Duke University
    Inventor: Christopher David Lascola
  • Patent number: 11083892
    Abstract: The present disclosure provides systems and methods relating to neuromodulation. In particular, the present disclosure provides systems and methods for minimally invasive, targeted, vagus nerve stimulation (pVNS), and the efficacy of this approach with respect to microglial activation and the amelioration of cognitive dysfunction. The systems and methods of neuromodulation disclosed herein can be used to facilitate the treatment of various diseases associated with pathological neural activity.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: August 10, 2021
    Assignee: DUKE UNIVERSITY
    Inventors: Niccolo Terrando, William Huffman, Warren Grill
  • Patent number: 11083604
    Abstract: A stent apparatus, system, and method that senses wall shear stress by measuring fluid flow at localized areas within the stent, that processes measured information through an integrated circuit, and selectively sends power to mechanically controllable stent surfaces which results in localized geometric changes. In various embodiments the stent apparatus, system, and method sends data to outside the body in real time.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: August 10, 2021
    Assignees: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC, THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DUKE UNIVERSITY
    Inventors: Erik V. Mukerjee, Jane A. Leopold, Amanda Randles
  • Publication number: 20210238682
    Abstract: Provided are compositions and methods for donor selection and prognosis of acute graft-versus-host disease. Provided is a method, which comprises obtaining a first biological sample from a first subject at risk of GVHD; detecting a level of miR-142-3p in the sample; and determining a risk of, prognosis of, or diagnosis of GVHD in the first subject. Provided also is a method for selecting a stem cell transplant donor, which comprises obtaining a first biological sample from a first subject and a second biological sample from a second subject, detecting a level of miR-142-3p in the first biological sample and the second biological sample; determining a ratio of the level of miR-142-3p in the second biological sample to the level of miR-142-3p in the first biological sample; determining the likelihood of the first subject will develop GVHD based on the ratio; and selecting a transplant donor based on the ratio.
    Type: Application
    Filed: April 19, 2019
    Publication date: August 5, 2021
    Applicant: DUKE UNIVERSITY
    Inventors: YOU-WEN HE, YU WANG, NELSON CHAO
  • Publication number: 20210238696
    Abstract: The present disclosure provides biomarkers for the identification of prostate cancer and methods of use. The present disclosure also provide biomarkers that can be used for determining risk of developing prostate cancer, aggressiveness of prostate cancer and survival rate for subpopulations of African American males or non-Hispanic white males.
    Type: Application
    Filed: April 9, 2021
    Publication date: August 5, 2021
    Applicants: Duke University, George Washington University
    Inventors: Jennifer Freedman, Yanru Wang, Hongliang Liu, Qingyi Wei, Daniel George, Steven Patierno, Bi-Dar Wang, Norman Lee
  • Patent number: 11077130
    Abstract: The invention provides compositions and methods to induce and boost antibody response, including but not limited to IgG responses binding to HIV-1 in a subject in need thereof, wherein the induced/boosted plasma level of the antibody responses, for example V3 and/or CD4 binding site antibody responses, is over a threshold level and is associated with reduced risk of maternal-to-child-transmission (MTCT) of HIV-1.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: August 3, 2021
    Assignee: DUKE UNIVERSITY
    Inventors: Barton F. Haynes, Sallie Permar, M. Anthony Moody, Feng Gao, Hua-Xin Liao, Georgia Tomaras, David C. Montefiori